Sanofi (NASDAQ:SNY) Upgraded at Sanford C. Bernstein

Sanofi (NASDAQ:SNY) was upgraded by investment analysts at Sanford C. Bernstein to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other analysts have also weighed in on SNY. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has an average rating of “Buy” and an average target price of $60.00.

Sanofi Trading Up 0.4 %

SNY stock opened at $54.34 on Thursday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a market capitalization of $137.91 billion, a PE ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57. The company’s 50 day moving average price is $49.24 and its two-hundred day moving average price is $52.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. As a group, analysts predict that Sanofi will post 3.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Hara Capital LLC lifted its holdings in Sanofi by 16.2% in the fourth quarter. Hara Capital LLC now owns 4,888 shares of the company’s stock worth $236,000 after buying an additional 680 shares during the period. Cardinal Capital Management boosted its position in shares of Sanofi by 1.9% during the fourth quarter. Cardinal Capital Management now owns 68,805 shares of the company’s stock valued at $3,318,000 after purchasing an additional 1,282 shares in the last quarter. Kestra Investment Management LLC purchased a new stake in Sanofi in the fourth quarter worth $84,000. Sierra Ocean LLC bought a new position in Sanofi in the fourth quarter worth $44,000. Finally, Keystone Financial Services lifted its position in Sanofi by 2.0% during the fourth quarter. Keystone Financial Services now owns 13,883 shares of the company’s stock valued at $670,000 after buying an additional 278 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.